SCHEMBL2931870

SCHEMBL2931870

Fc1ccc(-c2nc3nn(CCC4CCNCC4)cc3c(-c3ccc(F)cc3)c2-c2ccncc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.44
MAPK11 Q15759 8/20 0.44
RIPK3 Q9Y572 1/20 0.42
MAPK13 O15264 4/20 0.42
MAPK12 P53778 4/20 0.42
RAF1 P04049 2/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1D P48730 4/20 0.37
CSNK1A1 P48729 2/20 0.37
CSNK1E P49674 3/20 0.37
EGFR P00533 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GSK3B P49841 1/20 0.36
BRAF P15056 1/20 0.36
MAPK3 P27361 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1385787 0.90 RIPK3 (0.48) MAPK14MAPK11RIPK3MAPK13MAPK12
SCHEMBL1384346 0.86 MAPK14 (0.42) MAPK14MAPK11RIPK3MAPK13MAPK12
SCHEMBL1384099 0.84 MAPK14 (0.41) MAPK14MAPK11MAPK13MAPK12RAF1
SCHEMBL5784013 0.83 CSNK1D (0.38) MAPK14MAPK11RIPK3MAPK13MAPK12
SCHEMBL1386380 0.83 MAPK14 (0.42) MAPK14MAPK11MAPK13MAPK12RAF1
SCHEMBL2932159 0.82 ADORA2A (0.40) MAPK14MAPK11RIPK3MAPK13MAPK12
SCHEMBL1385273 0.81 SLC2A1 (0.39) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL2929622 0.81 MAPK14 (0.47) MAPK14MAPK11MAPK13MAPK12RAF1
SCHEMBL2931587 0.81 GPR119 (0.43) MAPK14MAPK11
SCHEMBL1386545 0.81 MAPK14 (0.50) MAPK14MAPK11RIPK3MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK11 40/4885RIPK3 725/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885RIPK3 689/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885RIPK3 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.